Monthly Archives: August 2019

TriMetals Mining to Receive US$ 25.8 Million from Bolivia

VANCOUVER, BC / ACCESSWIRE / August 29, 2019 / TriMetals Mining Inc. (TSX:TMI and TSX:TMI.B, OTCQB:TMIAF and OTCQB:TMIBF) (the “Company” or “TMI”) announces that today TMI and its wholly-owned subsidiaries South American Silver Limited (“SASL” or the “Claimant”) and Compania Minera Malku Khota S.A., have entered into an agreement (the “Settlement Agreement”) with the Government of the Plurinational State of Bolivia (“Bolivia”) to settle SASL’s international arbitration against Bolivia for the 2012 expropriation of the Malku Khota project, and to transfer to Bolivia the exploration data of the Malku Khota project owned by the Company (the “Data”).

On November 22, 2018, the Arbitral Tribunal of the Permanent Court of Arbitration issued an award (the “Award”), (see press release dated November 23, 2018), ordering Bolivia to provide compensation to SASL in the amount of US$18.7 million (the “Compensation”) and to pay interest thereon running from August 1, 2012 to the date of payment of the Compensation.

To avoid the time and expense of pursuing enforcement proceedings to collect the Award, which the Company and the third party funder of the arbitration (the “Fund”) agreed could take years with no guarantee of outcome, the Company and the Fund decided to initiate discussions with Bolivia with the view to obtaining a prompt settlement. From the first meeting with Bolivia, and during the meetings that ensued, it became known to the Company that prompt settlement would not be possible if the Company did not agree to transfer the Data to Bolivia as, for Bolivia, the Data was crucial to facilitate the further development of the project. The Company determined it was in its best interest to reach a prompt settlement with Bolivia by transferring its Data and by accepting a discount to the amount payable to the Claimant pursuant to the Award.

Pursuant to the Settlement Agreement, Bolivia has agreed to pay US$25,798,000 to the Company as a final settlement amount on or before September 5, 2019 and the Company agreed to transfer the Data to Bolivia. Bolivia will deduct $209,475 from the amount payable in satisfaction of the Tribunal’s cost order included in the Award. The Company expects to recover the US$209,475 from the Fund, as it relates to costs and expenses of the arbitration payable by the Fund.

Once paid, the Company will cease all legal activities related to the collection of the Award.

Matias Herrero, President & CEO of TMI commented, “Reaching a settlement with Bolivia and concluding the arbitration dispute is an important milestone for the Company and our shareholders. All efforts and attention can now be focused on growing and creating value for the Company, by exploring and further developing the mineral resources at the historic Gold Springs project in southern Utah and Nevada, both, top-ten mining jurisdictions in the world[1]”.

After taking into account the costs and expenses of the international arbitration proceedings (the “Malku Khota Arbitration Expenses”) which include the amount payable to the Fund pursuant to the terms of the litigation funding agreement, the reimbursement to the Company for arbitration expenses paid by it that were not covered by the Fund and the value of the Company’s Data transferred to Bolivia, the total redemption price of the Class B shares (the “Class B Shares Total Entitlement”) is approximately US$11.36 million. The amount to be reimbursed has not yet been finally determined as the Company is still receiving final invoices, but any changes are not expected to be material.

The Company has 60 days from the date of payment by Bolivia to redeem all 116,375,152 Class B shares outstanding. In the upcoming weeks, the Company will notify its Class B shareholders, their agents and/or brokers, about the procedure to redeem the Class B shares.

Following redemption of the Class B Shares and repayment of the Credit Facility (see press release of April 5, 2019), the Company will be debt free and expects to have approximately US$ 5 million of free available cash to fund exploration and development activities at the Gold Springs project and for general corporate costs.

About TriMetals Mining Inc.

TriMetals Mining Inc. (TSX:TMI and TSX:TMI.B, OTCQB:TMIAF and OTCQB:TMIBF) is a growth-focused gold exploration company creating value through the exploration and development of the near-surface Gold Springs gold-silver project in mining-friendly Nevada and Utah, U.S.A.

The Company’s Class B shares are listed on the Toronto Stock Exchange under the stock symbol “TMI.B” and on the OTCQB under the stock symbol TMIBF and have no interest in the properties or assets of the Company other than the collective entitlement to 85% of the net cash, if any (after deducting all costs, taxes and expenses and the amount due to a third party that funded the costs of the arbitration), received by the Company from an award or settlement in relation to South American Silver’s arbitration proceeding against Bolivia for the expropriation of the Malku Khota project in 2012.

TriMetals Mining Inc. Contact:
Matias Herrero
Chief Executive Officer
mherrero@trimetalsmining.com

Forward-looking Statements

Certain statements contained herein constitute “forward-looking information” under applicable Canadian securities laws (“forward-looking statements”). Forward-looking statements look into the future and provide an opinion as to the effect of certain events and trends on the business. Forward-looking statements may include words such as “would”, “will”, “expect” and similar expressions. The amount of the Class B Shares Total Entitlement, the Company’s expectation to be debt-free and its expectation of the amount of free available cash to be available to it each constitutes a forward-looking statement. These forward-looking statements are based on current expectations and entail various risks and uncertainties. Actual results may materially differ from expectations if known and unknown risks or uncertainties affect our business or if our estimates or assumptions prove inaccurate. Factors that could cause results or events to differ materially from current expectations expressed or implied by the forward-looking statements, include, but are not limited to, Bolivia not paying the settlement amount by September 5, 2019, and other risks more fully described in the Company’s Annual Information Form and continuous disclosure documents, which are available on SEDAR at www.sedar.com.

Readers are cautioned not to place undue reliance on the forward-looking statements contained in this press release. Except as required by law, the Company assumes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Unless otherwise indicated, forward-looking statements in this press release describe the Company’s expectations as of the date hereof.

[1] Fraser Institute’s most recent annual survey of mining companies published on February 28, 2019.

SOURCE: TriMetals Mining Inc.

ReleaseID: 557882

Altus Strategies PLC Quarterly Report & Financial Statements

DIDCOT, UK / ACCESSWIRE / August 29, 2019 / Altus Strategies Plc (AIM:ALS & TSX-V:ALTS), the Africa focused project and royalty generator, announces that it has today published its unaudited financial results for the three month and six month periods ending 30 June 2019 and the Management Discussion & Analysis for the three month period ending 30 June 2019. These documents have been posted on the Company’s website www.altus-strategies.com and are also available on SEDAR at www.sedar.com.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

For further information you are invited to visit the Company’s website www.altus-strategies.com or contact:

Altus Strategies Plc

Steven Poulton, Chief Executive

Tel: +44 (0) 1235 511 767

E: info@altus-strategies.com

SP Angel (Nominated Adviser)

Richard Morrison / Soltan Tagiev

Tel: +44 (0) 20 3470 0470

SP Angel (Broker)

Abigail Wayne / Richard Parlons

Tel: +44 (0) 20 3470 0471

Blytheweigh (Financial PR)

Tim Blythe / Camilla Horsfall

Tel: +44 (0) 20 7138 3204

About Altus Strategies Plc

Altus is a London (AIM:ALS) and Toronto (TSX-V:ALTS) listed project and royalty generator in the mining sector with a focus on Africa. Our team creates value by making mineral discoveries across multiple licences. We enter joint ventures with respected groups and our partners earn interest in these discoveries by advancing them toward production. Project milestone payments we receive are reinvested to extend our portfolio, accelerating our growth. The portfolio model reduces risk as our interests are diversified by commodity and by country. The royalties generated from our portfolio of projects are designed to yield sustainable long-term income. We engage constructively with all our stakeholders, working diligently to minimise our environmental impact and to promote positive economic and social outcomes in the communities where we operate.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this news release contain forward-looking information. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. Such factors include without limitation the completion of planned expenditures, the ability to complete exploration programmes on schedule and the success of exploration programmes. Readers are cautioned not to place undue reliance on the forward-looking information, which speak only as of the date of this news release.

Neither the TSX Venture Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Altus Strategies Plc

ReleaseID: 557875

Homeopathy Market 2019 Size, Share, Regions, Global Players, Industry Growth, Drivers, Applications, Type, Source – Forecast till 2023

As per the Analysis offered by Market Research Future (MRFR), Global Homeopathy Market Will Capture an impressive growth rate during the review period (2019-2023).

Pune, India – August 29, 2019 /MarketersMedia/ —

Homeopathy Market Global Players:

Boiron Group, Heel, Nelson & Co. Ltd., GMP Laboratories, Homeocan Inc., Hyland, And Weleda. 

Homeopathy Market Global Overview:

The Global Homeopathy Market is expected to grow at a robust CAGR of 14.6% over the forecast period from 2017 to 2023, according to the latest research report from Market Research Future (MRFR). The global homeopathy market is mainly driven by the growing demand for alternative medicine that is free from the encumbrances of the scientific method and evidence-based progression. The growing number of people willing to believe in lifestyle and medicinal systems that don’t fit the conventional model of natural laws is likely to be a major driver for the global homeopathy market over the forecast period.

The growing aversion to allopathic medicine, a constant rise in demand for convenient dosages of a variety of medicines & an increase in consumer confidence about alternate treatment methodologies are all significantly fueling the market growth. Moreover, increasing number of patients suffering from different chronic diseases have increased the demand for homeopathy medicine and developing regions showing a strong opportunity for homeopathy market.

Request Free Sample Copy at https://www.marketresearchfuture.com/sample_request/4970

Regional Analysis:

Europe is the largest regional market for homeopathic medicine and is likely to reach a valuation of USD 11,347.7 million by 2023. The origin of homeopathy was in Europe, which gives the region the first mover advantage in the homeopathy market.

The Middle East and Africa is the fastest growing regional market for homeopathic medicine and is likely to exhibit a CAGR of 16.09% over the forecast period.

Segmentation:

The Global Homeopathy Market is segmented on the basis of type, application, source, end user, and region.

On the basis of type, the global homeopathy market is segmented into dilutions, tincture, biochemics, ointments, tablets, and others. Tinctures are the fastest growing segment and are expected to exhibit a CAGR of 14.82% over the forecast period.

On the basis of the application, the homeopathy market is segmented into analgesic and antipyretic, respiratory, neurology, immunology, gastroenterology, dermatology, and others.

On the basis of the source, the market is segmented into plants, animals, and minerals.

On the basis of end user, the Homeopathy Market is segmented into homeopathic clinics, hospitals, retailers, e-retailers, research laboratories, and others.

TOC:

1  Report Prologue$ 1,350.00

2  Market Introduction$ 0.00

3  Research Methodology$ 0.00

4  Market Dynamics$ 950.00

5  Market Factor Analysis$ 950.00

6  Global Homeopathy Market, by Type$ 1,650.00

7  Global Homeopathy Market, by Applications$ 1,650.00

8  Global Homeopathy Market, by Source$ 1,650.00

9  Global Homeopathy Market, by End User$ 1,650.00

10  Global Homeopathy Market, by Region$ 1,650.00

11  Competitive Landscape$ 1,050.00

12  Company Profiles$ 900.00

13  MRFR Conclusion$ 750.00

14  Appendix

Access Full Report at https://www.marketresearchfuture.com/reports/homeopathy-market-4970

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Info:
Name: Abhishek Sawant
Email: Send Email
Organization: Market Research Future
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune – 411028 Maharashtra, India
Phone: 6468459312
Website: https://www.marketresearchfuture.com/reports/homeopathy-market-4970

Source URL: https://marketersmedia.com/homeopathy-market-2019-size-share-regions-global-players-industry-growth-drivers-applications-type-source-forecast-till-2023/88913503

Source: MarketersMedia

Release ID: 88913503

Cystic Fibrosis Market Synopsis by Size Share, Growth, Major Players, Global Players, Regional Analysis and Outlook till 2023

The Report of “Cystic Fibrosis Market” Research Future Covers the Information like Market, Prominent Players and Cystic Fibrosis Market Segmentation, Regional Outlook, End-User and Forecast to 2023.

Pune, India – August 29, 2019 /MarketersMedia/ —

Cystic Fibrosis Market Global Players:

Leading players in the global cystic fibrosis market include Vertex Pharmaceuticals, AbbVie, Novartis, Pharmaxis, Forest Laboratories, Chiesi Farmaceutici, Genentech, Gilead Sciences, and F. Hoffman-La Roche.

Cystic Fibrosis Market Global Overview:

The Global Cystic Fibrosis Market is expected to grow at a 13.5% CAGR over the forecast period from 2016 to 2022, according to the latest research report from Market Research Future (MRFR). The global cystic fibrosis market is driven mainly by the growing support to cystic fibrosis research and growing economic investment in the research efforts from governments. The report predicts the likely growth trajectory of the global cystic fibrosis market over the forecast period with the help of a detailed analysis of the market’s historical growth trajectory and leading market drivers and restraints. The leading players operating in the global cystic fibrosis market are also analyzed in the report to provide readers with a clear picture of the market’s competitive landscape. The global cystic fibrosis market is expected to reach a value of USD 1,192.2 million by 2022.

Request Free Sample Copy at https://www.marketresearchfuture.com/sample_request/1825

Cystic fibrosis is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, resulting in the CFTR protein not functioning properly. This results in inadequate retention of water near the cell surface, which makes the mucus in the human body thick and sticky. Cystic fibrosis presents as a series of lung infections making it progressively harder for the patient to breathe. The mucus accumulates in the lungs and can also trap pathogens and other foreign bodies, which can lead to inflammation, respiratory failure, and other problems.

The growing support from the Cystic Fibrosis Foundation (CFF) to research efforts is likely to be a major driver for the global cystic fibrosis market over the forecast period. CFF has invested more than USD 400 million in research efforts into finding out more about cystic fibrosis and is likely to remain a powerful driver for the cystic fibrosis market over the forecast period. On the other hand, the cystic fibrosis market is hindered by the high costs of the drugs currently available in the market.

Industry Updates:

In 2019, the U.K. NHS presented an offer to Vertex for its cystic fibrosis drug Orkambi. The first offer of more than GBP 500 million was rejected by Vertex, with more talks planned in March 2019.

Segmentation:

On the basis of treatment method, the global cystic fibrosis market is segmented into medication, devices, and other treatments.

The medication treatment segment accounted for a dominant 76.4% of the global cystic fibrosis market in 2016 and is likely to exhibit the highest 14% CAGR over the forecast period. Despite the high share of the medication segment, the global cystic fibrosis market’s growth prospects are hindered by the high costs of the medication available in the market, as this prices out several consumer demographics, particularly in emerging, high-volume markets such as Asia Pacific.

Regional Analysis:

The global cystic fibrosis market is segmented by region into North America, Europe, Asia Pacific, and the Middle East and Africa.

North America is likely to remain the major regional segment of the global cystic fibrosis market over the forecast period due to the growing medical research sector in the region. The strong presence of the CFF in North America as well as the growing interest in cystic fibrosis research in the region are likely to be the major drivers for the cystic fibrosis market in North America over the forecast period. The North America cystic fibrosis market is expected to reach a value of USD 521 million by 2022. Cystic fibrosis is a relatively rare disease, with around 70,000 people estimated to be suffering from it in 2017. The CFF has played a vital role in the development of the global cystic fibrosis market, as before the initiation of the foundation, research into cystic fibrosis was severely lacking. In 2018, the CFF provided USD 100 million to the Infection Research Initiative, along with funding research into other aspects of cystic fibrosis, such as the inflammation and gastrointestinal problems associated with the disease.

Europe is expected to exhibit the fastest growth in the global cystic fibrosis market, growing at a robust 14.1% CAGR over the forecast period. Europe and North America hold comparable shares in the global cystic fibrosis market and are likely to remain the leading regional parties over the forecast period.

TOC:

1  INTRODUCTION$ 0.00

2  RESEARCH METHODOLOGY$ 1,350.00

3  MARKET DYNAMICS$ 950.00

4  MARKET FACTOR ANALYSIS$ 950.00

5  GLOBAL CYSTIC FIBROSIS MARKET, BY DIAGNOSTIC TEST $ 1,650.00

6  GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT$ 1,650.00

7  GLOBAL CYSTIC FIBROSIS MARKET, BY DRUG TYPE$ 1,650.00

8  GLOBAL CYSTIC FIBROSIS MARKET, BY REGION$ 1,650.00

9  COMPETITIVE LANDSCAPE$ 1,050.00

10  COMPANY PROFILE$ 900.00

11  List of Tables$

12  List of Figures

Browse Full Report at https://www.marketresearchfuture.com/reports/cystic-fibrosis-market-1825

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Info:
Name: Abhishek Sawant
Email: Send Email
Organization: Market Research Future
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune – 411028 Maharashtra, India
Phone: 6468459312
Website: https://www.marketresearchfuture.com/reports/cystic-fibrosis-market-1825

Source URL: https://marketersmedia.com/cystic-fibrosis-market-synopsis-by-size-share-growth-major-players-global-players-regional-analysis-and-outlook-till-2023/88913516

Source: MarketersMedia

Release ID: 88913516

SHAREHOLDER ALERT – GTT Communications, Inc. (GTT) – Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: September 30, 2019

NEW YORK, NY / ACCESSWIRE / August 29, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed GTT Communications, Inc.(“GTT” or the Company”) (NYSE:GTT)and certain of its officers, on behalf of shareholders who purchased or otherwise acquired GTT securities between February 26, 2018 and July 1, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm’s site:www.bgandg.com/gtt.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) there were delays in migrating Interoute Communications Holdings S.A.’s (“Interoute”) legacy systems and processes into GTT’s client management database system; (2) Interoute had made a strategic priority shift to sell cloud services that was a higher percentage of Interoute’s sales in the two years leading up to the acquisition; (3) a material percentage of the Interoute sales representatives were not productive at selling GTT’s core cloud networking services; (4) GTT was unable to yield as many Interoute salespeople because Interoute had hired many sales people focused on cloud services and allowed underperforming sales representatives to remain at Interoute; and (5) as a result, GTT’s public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/gtt or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in GTT you have until September 30, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz |
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557881

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of RLGY, ABMD and GVA

NEW YORK, NY / ACCESSWIRE / August 29, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Realogy Holdings Corp. (NYSE:RLGY)
Class Period: February 24, 2017 to May 22, 2019
Lead Plaintiff Deadline: September 9, 2019

During the class period, Realogy Holdings Corp. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Realogy was engaged in anticompetitive behavior by requiring property sellers to pay the commissions of a buyer’s broker at an inflated rate; (2) Realogy’s anticompetitive actions would prompt the U.S. Department of Justice (“DOJ”) to open an antitrust investigation into the real estate industry’s practices regarding brokers’ commissions; and (3) as a result, Defendants’ statements about the Realogy’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in RLGY: http://www.kleinstocklaw.com/pslra-1/realogy-holdings-corp-loss-submission-form?id=3250&from=1

Abiomed, Inc. (NASDAQ:ABMD)
Class Period: January 31, 2019 to July 31, 2019
Lead Plaintiff Deadline: October 7, 2019

The complaint alleges Abiomed, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Abiomed’s revenue growth was in decline; (ii) the Company did not have a sufficient plan in place to stem its declining revenue growth; (iii) the Company was unlikely to restore its revenue growth over the next several fiscal quarters; (iv) consequently, Abiomed was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company’s prior projections and market expectations; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ABMD: http://www.kleinstocklaw.com/pslra-1/abiomed-inc-loss-submission-form?id=3250&from=1

Granite Construction Incorporated (NYSE:GVA)
Class Period: October 26, 2018 to August 1, 2019
Lead Plaintiff Deadline: October 15, 2019

During the class period, Granite Construction Incorporated allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company had assumed certain risks in connection with its heavy civil joint venture projects bid between 2012 and 2014; (2) there was an “untenable” imbalance of risk sharing between the Company and the joint venture project owners; (3) as a result, the Company was reasonably likely to incur additional project costs for its joint venture projects; (4) the Company was reasonably likely to incur additional costs in connection with certain project disputes; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in GVA: http://www.kleinstocklaw.com/pslra-1/granite-construction-incorporated-loss-submission-form?id=3250&from=1

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 557880

SHAREHOLDER ALERT – L Brands, Inc. (LB) – Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Plaintiff Deadline: September 23, 2019

NEW YORK, NY / ACCESSWIRE / August 29, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against L Brands, Inc. (“L Brands” or the “Company”) (NYSE:LB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired L Brands securities between May 31, 2018 through November 19, 2018, both dates inclusive. Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/lb.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Victoria’s Secret and PINK businesses were having a material adverse effect on L Brands’ cash flow, liquidity and debt levels; (2) Defendants lacked a reasonable basis for their positive statements about the ability of the Company to sustain its dividend; (3) the MD&A disclosures in filings L Brands made with the SEC were materially false and misleading; (4) the risk factor disclosures in filings L Brands made with the SEC were materially false and misleading; (5) the representations about L Brands’ disclosure controls in filings the Company made with the SEC were materially false and misleading; (6) the certifications issued by Defendants Wexner and Burgdoerfer on L Brands disclosure controls were materially false and misleading; (7) as a result, defendants’ statements about L Brands’ business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/lbor you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in L Brands you have until September 23, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 557878

Europe Ambulatory Surgical Centers Market Expected to Reach Over $32 Bn by 2024

Graphical Research has reported the addition of the “Ambulatory Surgical Centers Market: Europe Industry Analysis and Opportunity Assessment 2019 – 2024″ report to their offering.

India – August 29, 2019 /MarketersMedia/ —

Growing disease burden coupled with rapidly ageing population is the key factor driving Europe ambulatory surgical centers market growth. Developments in ambulatory surgical centers aimed at achieving faster disease diagnosis, minimized costs and enhanced patient care will favor business growth. Additionally, rising awareness among people regarding early disease diagnosis and growing inclination towards ASCs for high quality and affordable treatments will upsurge ambulatory surgical centers industry growth over the forecast period.

Request for a sample of this report @ https://www.graphicalresearch.com/request/1148/sample

According to the Graphical Research new growth forecast report titled “Europe Ambulatory Surgical Centers Market Size By Specialty Type (Single-specialty, Multi-specialty), By Service (Diagnosis, Treatment), By Ownership (Physician Only, Hospital Only, Physician & Hospital, Corporation Only, Physician & Corporation, Hospital & Corporation), By Surgery Type (Dental, Otolaryngology, Endoscopy, Obstetrics/Gynecology, Ophthalmology, Orthopedic, Cardiovascular, Neurology, Plastic, Podiatry), Industry Analysis Report, Country Outlook (Germany, UK, France, Italy, Spain, Russia, Poland, Denmark, Netherlands, Norway, Portugal, Sweden, Czech Republic, Belgium), 2018 – 2024”, estimated to exceed USD 32 Billion by 2024

Few of the prominent players in Europe ambulatory surgical centers market include Alan Cumming Day Surgery Unit, BMI Blackheath Hospital Outpatient Centre, London Day Surgery Centre, Central Institute of Mental Health, Chelsea and Westminster Hospital, Vitanas clinic and day hospital, Auxologico Ariosto, Ghent University Hospital, Zudecche Day Surgery and Balgrist University Hospital. Industry players are taking numerous initiatives to acquire higher market share and strengthen their market position. Moreover, increasing the number of ASCs throughout the region will help in enhancing company’s revenue growth.

Furthermore, favorable government support to encourage procedures to be performed on day basis owing to advantages such as shortened hospital stays, early mobilization of patients, reduced hospital-acquired infections and improved quality of postoperative recovery will foster industry growth. For instance, NHS and Government of UK are actively promoting day surgery practice with an aim to perform around 75% of procedures in day surgery centers in the country. Moreover, presence of British Association of Day Surgery (BADS) providing education about day surgery to patients and professionals as well as supporting research and quality improvement projects pertaining to day surgeries will spur the business size. However, low physician-to-patient ratio in certain economies may impede the market growth.

Hospital only segment was valued more than 1 billion in 2017 and is anticipated to show considerable growth during the forthcoming years. Segment growth is attributable to increasing healthcare cost, technological development that enable rapid recovery and minimally invasive surgical techniques that enable hospitals to carry out most of the surgical procedures in hospital owned ASCs.

Orthopedic surgery segment is estimated to show lucrative CAGR of 4.8% over the analysis timeline. Segment growth can be attributable to growing incidence of osteoarthritis (degenerative bone disease), obesity and osteoporosis in the region. Sedentary lifestyle, greater life expectancy and rapid ageing will serve to be prime factors surging the demand for orthopedic procedures, thereby fostering the segment growth.

Multi-specialty segment accounted for around 43% revenue share in 2017 owing to diversified number of services offered by the multi-specialty ambulatory surgical centers. Technological improvements that enable multispecialty centers to perform substantial number of acuity cases will further upsurge the revenue size of multi-specialty ASCs.

Treatment segment is expected to grow substantially with revenue of over USD 25 billion by 2024. Cost-effectiveness associated with treatment offered at ambulatory centers will act as primary driver for the segment growth. Growing demand for high quality care at comparatively lower-cost will favor business growth over the coming years.

France ambulatory surgical centers market is estimated to show more than 4.5% CAGR over the forecast timeframe. Increasing prevalence of chronic diseases such as cardiovascular diseases, diabetes, cancer and others will fuel the need to shift towards day surgeries. Ambulatory surgery centers offering improved quality of care to patients, well-developed facilities, reduced hospital stay as well as enhanced patient satisfaction will surge the number of surgeries being performed in these centers. Moreover, continuous medical progress along with incentive pricing for surgical procedures pave the way for ambulatory surgeries to become a standard of surgical care in the country, thus, fostering the business growth.

Segments we cover:

Europe Ambulatory Surgical Centers Market Statistics, By Ownership

Physician Only
Hospital Only
Corporation Only
Physician & Hospital
Physician & Corporation
Hospital & Corporation

Europe Ambulatory Surgical Centers Market Growth, By Surgery Type

Dental
Otolaryngology
Endoscopy
Obstetrics/Gynecology
Ophthalmology
Orthopedic
Cardiovascular
Neurology
Plastic
Podiatry
Others

Europe Ambulatory Surgical Centers Market Trends, By Specialty Type

Single-specialty
Multi-specialty

Europe Ambulatory Surgical Centers Market Analysis, By Service

Diagnosis
Treatment

Browse key industry insights along with Table of Content @ https://www.graphicalresearch.com/industry-insights/1148/europe-ambulatory-surgical-centers-market

Related Reports;

Asia Pacific Ambulatory Surgical Centers Market : https://www.graphicalresearch.com/industry-insights/1170/asia-pacific-ambulatory-surgical-centers-market

North America Ambulatory Surgical Centers Market : https://www.graphicalresearch.com/industry-insights/1144/north-america-ambulatory-surgical-centers-market

About Graphical Research:

Graphical Research is a business research firm that provides industry insights, market forecast and strategic inputs through granular research reports and advisory services. We publish targeted research reports with an aim to address varied customer needs, from market penetration and entry strategies to portfolio management and strategic outlook. We understand that business requirements are unique: our syndicate reports are designed to ensure relevance for industry participants across the value chain. We also provide custom reports that are tailored to the exact needs of the customer, with dedicated analyst support across the purchase lifecycle.

Contact Info:
Name: Parikhit B.
Email: Send Email
Organization: Graphical Research
Website: https://www.graphicalresearch.com/industry-insights/1148/europe-ambulatory-surgical-centers-market

Source URL: https://marketersmedia.com/europe-ambulatory-surgical-centers-market-expected-to-reach-over-32-bn-by-2024/88913449

Source: MarketersMedia

Release ID: 88913449

San Antonio Botanical Garden Names New Chief Executive Officer

San Antonio Botanical Garden Names New CEO. As only the fourth female President of the Board of the American Public Garden Association, Sabina brings innovative ideas generated among this network of 600 member gardens and 6,000 individual members.

San Antonio, United States – August 29, 2019 /PressCable/ —

San Antonio Botanical Garden Names New CEO

SAN ANTONIO – The San Antonio Botanical Garden announced today it has selected Sabina Carr as Chief Executive Officer. As Vice President of Marketing at the Atlanta Botanical Garden for the past 16 years, Mrs. Carr leads the strategic vision, brand identity, and diversification of revenue streams for one of the nation’s leading public gardens. From 2014-2016, she served as President of the Board of the American Public Garden Association, the preeminent professional organization for botanical gardens and arboreta. Sabina will begin leading the Garden on November 6.

“Sabina’s vision and experience in large public gardens makes her the right leader for the Garden’s future as we build on the success of the Garden’s recent $40 million capital investment. She brings a proven track record, leading teams that tripled annual visitation, membership, and the operational budget during her tenure in Atlanta,” said John Troy, President of the Botanical Garden Board.

The Botanical Garden launched a national search for the Chief Executive Officer in April by engaging the Chicago-based firm of Kittleman & Associates, LLC, an executive recruiting company that works exclusively with nonprofit organizations. “We cast a wide net to find the person with the highest level of leadership skills, career experience, and industry knowledge to lead the Garden in our mission to connect people with plants,” said Mary Ann Beach, Chair of the Board Search Committee. “In every aspect, Sabina is the leader who understands the impact of public gardens in our lives and has the vision and strategic leadership skills to advance the Garden’s mission to serve our entire community.

As only the fourth female President of the Board of the American Public Garden Association, Sabina brings innovative ideas generated among this network of 600 member gardens and 6,000 individual members. Prior to joining the Atlanta Botanical Garden, Sabina held marketing and advertising positions with American Express, Conde Nast Publishing, and Saatchi & Saatchi Advertising.

“I am honored to join the Garden during this remarkable time of growth to further the ambitious accomplishments of the Board and staff,” said Sabina. “Great cities have great gardens and the botanical garden is the place to forge deep connections to plants and foster an understanding of the natural world. The recent expansion and soon to be completed Education and Events Center provides an enormous opportunity for this Garden to be relevant to the community for generations to come.”

About the San Antonio Botanical Garden

Opened in 1980, the mission of the Botanical Garden is to inspire people to connect with the plant world and understand the importance of plants in our lives. It features 38 acres of nature spaces located off Broadway near the City center. The Garden connects visitors to horticultural displays, Texas native plant areas, a culinary garden, an outdoor CHEF Teaching Kitchen, and a Family Adventure Garden. In March they will open an Education and Event Center, an event lawn, and a new administration building. The Garden is home to the award-winning Lucille Halsell Conservatory. Both timeless and specific, natural and man-made, the Lucille Halsell Conservatory changed San Antonio’s skyline in 1988. Designed by Emilio Ambasz, it has welcomed millions of visitors to explore unique plants and ecosystems from around the world.

Contact Info:
Name: Connie Swann
Email: Send Email
Organization: San Antonio Botanical Garden
Address: 555 Funston Place, San Antonio, TX 78209, United States
Phone: +1-210-536-1400
Website: http://www.sabot.org/

Source: PressCable

Release ID: 88913327

The Best Hemp Oil: Does Hemp Oil Help Relieve Pain?

MIAMI, FL / ACCESSWIRE / August 29, 2019 / TRYMFit.com:

Which Is the reason many who suffer from pain have turned to hemp oil CBD

The number of American’s using hemp oil for pain relief is rapidly rising, showing that cannabis, along with the cannabinoids it produces, can do much more than create an intoxicating high, it can aid in healing your body.

Hemp oil offers an appeal alternative to OTC medications that don’t offer adequate pain relief, or, the assortment of toxic prescribed pharmaceuticals which can carry significant side effects which often times negatively impact your health and quality of life.

What is the best hemp oil for pain?

TRYMFit.com has tested, analyzed and reviewed hundreds of CBD products, and is officially recommending the bioMD+ 1,000mg Natural Full-Spectrum CBD Oil as the best CBD oil for pain.

When to use hemp oil for pain?

The human body contains a specialized system called the endocannabinoid system (ECS), which is involved in regulating a variety of functions including sleep, appetite, pain and immune system response. The body produces endocannabinoids, which are neurotransmitters that bind to cannabinoid receptors in your nervous system.

Hemp oil which it is possible to use to make creams or gels that people can apply to the skin of the areas affected by arthritis. You can use it when there is no relief in other previous treatments. Studies have shown that hemp oil may help reduce chronic pain by impacting endocannabinoid receptor activity, reducing inflammation and interacting with neurotransmitters.

How Does CBD Help Relieve Pain?

There are two main ways that CBD can help us feel better. First, CBD can change the body’s perception of pain. Because of this, studies have found that cannabinoids like CBD have a promising result for the treatment of neuropathic pain. CBD is also able to reduce inflammation in the body, which can lead to a similar effect that over the counter pain relievers have (think Tylenol or ibuprofen).

If you’re experiencing joint, back, muscle, or other chronic pain, take a moment to find out how CBD can help you manage your pain and feel better without the side effects.

You can read the full list of top CBD Brands here: https://trymfit.com/compare-cbd-oil-tinctures/

How to Use Hemp Oil for Pain?

There are a number of questions to address in order to ensure users experience the full benefits of hemp oil for pain relief. One online resource providing clarity is the team at TRYMFit.com.

TRYMFit.com offers cannabis related educational content, news, and unbiased reviews of the top-rated hemp and CBD oil brands available on the market. An example of their commitment to educating consumers about hemp oil, is their article titled, “CBD Dosage for Pain”

.

CONTACT:

Tim McComsey
TrymFit.com
(770) 239-7752
TRYMFit@gmail.com

SOURCE: TRYMFit.com

ReleaseID: 557873